Regenxbio to host investor event on sura-vec wet AMD program ahead of pivotal data readout
RGNX•Regenxbio will host an investor event on Oct. 20, 2026, in New York, with a webcast option, to discuss its sura-vec wet AMD program ahead of pivotal topline data expected in the fourth quarter of 2026.
1. Investor event
Regenxbio plans to review its wet age-related macular degeneration program, including the ATMOSPHERE and ASCENT pivotal trials, with outside retina specialists at the Oct. 20 event, scheduled for 1:00 p.m. ET.
